Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-12-02
2010-12-21
Steadman, David J (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C514S012200
Reexamination Certificate
active
07855274
ABSTRACT:
The present invention relates to recombinant factor VIII having a specific activity that is higher than that of the corresponding wild-type factor VIII. The present invention also relates to methods of making and using the recombinant factor VIII. The present invention also relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
REFERENCES:
patent: 5422260 (1995-06-01), Kaufman et al.
patent: 5576291 (1996-11-01), Curtis et al.
patent: 5859204 (1999-01-01), Lollar
patent: 5880327 (1999-03-01), Lubon et al.
patent: 5998589 (1999-12-01), Buettner et al.
patent: 6271025 (2001-08-01), Négrier et al.
patent: 6376463 (2002-04-01), Lollar
patent: 6458563 (2002-10-01), Lollar
patent: 6593291 (2003-07-01), Green et al.
patent: 6599724 (2003-07-01), Mikaelsson et al.
patent: 6759216 (2004-07-01), Lollar
patent: 6770744 (2004-08-01), Lollar
patent: 6780614 (2004-08-01), Négrier et al.
patent: 6800461 (2004-10-01), Négrier et al.
patent: 2003/0125232 (2003-07-01), Griffin et al.
patent: 2003/0166536 (2003-09-01), Lollar et al.
patent: 2004/0092442 (2004-05-01), Kaufman et al.
patent: 2004/0147436 (2004-07-01), Kim et al.
patent: 2004/0197875 (2004-10-01), Hauser et al.
patent: 2005/0100990 (2005-05-01), Saenko et al.
Wakabayashi et al., “Ca2+ Binding to Both the Heavy and Light Chains of Factor VIII Is Required for Cofactor Activity,” Biochem. 41:8485-8492 (2002).
Wakabayashi et al., “Residues 110-126 in the Factor VIII Heavy Chain Contain a CA2+ Binding Site Required for Cofactor Activity,”Blood102(11):542a (2003).
Amano et al., “Mutation at either ARg336 or Arg562 in Factor VIII is Insufficient for Complete Resistance to Activated Protein C (APC)-Mediated Inactivation: Implications for the APC Resistance Test,”Thromb Haemost79:557-563 (1998).
Swaroop et al., “Mutagenesis of Potential Immunoglobulin-Binding Protein-Binding Site Enhances Secretion of Coagulation Factor VIII,”J Biol Chem272(39):24121-24124 (1997).
Wakabayahi et al., “Factor VIII: E113A Represents a High Specific Activity Factor VIII Arising From a Single Point Mutation within the Ca2+ Binding Site,”Blood104(11):479a (2004).
Wakabayashi et al., “Residues 110-126 in the A1 Domain of Factor VIII Contain a Ca2+ Binding Site Required for Cofactor Activity,”J Biol Chem279(13:12677-12684 (2004).
Sarafanov et al., “Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-Related Protein,”J Biol Chem276(15):11970-11979 (2001).
Lenting et al., “The Sequence of Glu1811-Lys1818 of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor 1X,”J Biol Chem271(4):1935-1940 (1996).
Gale et al., “An Engineered lnterdomain Disulfide Bond Stabilizes Human Blood Coagulation Factor VIIIa,”J Thrombosis and Haemostasis1(9):1966-1971 (2003) (abstract only).
Pipe et al., “Characterization of a Genetically Engineered Inactivation-Resistant Coagulation Factor VIIIa,”Proc Natl Acad Sci USA94:11851-11856 (1997).
Lenting et al., “The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function,”Blood92(11):3983-3996 (1998).
Hernández (editor), “Factor VIII/von Willebrand Factor Complex in Hemophilia A Treatment Recent Findings, Emerging Major Role,”Journal of Hematology88(9):1-27 (2003).
Fay Philip J.
Wakabayashi Hironao
Nixon & Peabody LLP
Steadman David J
Tsay Marsha M
University of Rochester
LandOfFree
Recombinant factor VIII having increased specific activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant factor VIII having increased specific activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant factor VIII having increased specific activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220117